Company Description

Optigo Biotherapeutics have developed proprietary precision targeted protein domains that bind to various components of the vitreous gel. These can be fused to existing and future retinal biologics, creating bi-specific molecules that anchor the biologic to the vitreous gel with the aim of significantly extending half-life and duration of action without impacting efficacy.